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A repeat expansion in C9ORF72 causes frontotempo-
ral dementiaandamyotrophic lateral sclerosis (c9FTD/
ALS). RNA of the expanded repeat (r(GGGGCC)exp)
forms nuclear foci or undergoes repeat-associated
non-ATG (RAN) translation, producing ‘‘c9RAN pro-
teins.’’ Since neutralizing r(GGGGCC)exp could inhibit
these potentially toxic events, we sought to identify
small-molecule binders of r(GGGGCC)exp. Chemical
and enzymatic probing of r(GGGGCC)8 indicate that
it adopts a hairpin structure in equilibrium with
a quadruplex structure. Using this model, bioactive
small molecules targeting r(GGGGCC)exp were de-
signed and found to significantly inhibit RAN trans-
lation and foci formation in cultured cells expressing
r(GGGGCC)66 and neurons transdifferentiated from
fibroblasts of repeat expansion carriers. Finally, we
showthatpoly(GP)c9RANproteinsarespecificallyde-
tected in c9ALS patient cerebrospinal fluid. Our find-
ings highlight r(GGGGCC)exp-binding small molecules
as apossible c9FTD/ALS therapeutic andsuggest that
c9RAN proteins could potentially serve as a pharma-
codynamic biomarker to assess efficacy of therapies
that target r(GGGGCC)exp.NeINTRODUCTION
Frontotemporal dementia (FTD) and amyotrophic lateral scle-
rosis (ALS) are overlapping neurodegenerative diseases with
no effective treatment. Success in developing a treatment will
require a well-orchestrated effort that addresses multiple as-
pects of the drug discovery process, including target identifi-
cation and validation, as well as the identification of biomarkers
to assess efficacy of potential therapies in clinical trials. These
endeavors have been hampered by an incomplete understand-
ing of FTD and ALS pathogenesis. However, with the discovery
that a GGGGCC repeat expansion in C9ORF72 is the most
common genetic cause of FTD and ALS (DeJesus-Hernandez
et al., 2011; Renton et al., 2011), a new therapeutic target has
come to light.
Two putative pathomechanisms of ‘‘c9FTD/ALS’’ involve RNA
transcribed from the expansion. First, these transcripts (termed
r(GGGGCC)exp) may cause toxicity through the formation
of nuclear RNA foci that sequester various RNA-binding proteins
(for review, see Gendron et al., 2014). Second, r(GGGGCC)exp
undergoes repeat-associated non-ATG (RAN) translation,
producing ‘‘c9RAN proteins’’ that form neuronal inclusions
throughout the central nervous system (Ash et al., 2013; Mori
et al., 2013b). Consequently, neutralizing or degrading
r(GGGGCC)exp holds promise as a therapeutic approach for
c9FTD/ALS. Indeed, antisense oligonucleotides to C9ORF72
transcripts suppress features associated with the repeaturon 83, 1043–1050, September 3, 2014 ª2014 Elsevier Inc. 1043
Figure 1. Probing r(GGGGCC)n Secondary
Structures
(A) CD spectra of r(GGGGCC)4,6,8 and r(CGG)12 in
the presence of various monovalent cations.
(B) Optical melting curves for r(GGGGCC)4,6,8 and
r(CGG)12monitored at 295 nm. RNA samples (4 mM)
were folded prior to recording CD spectra (20C)
and optical melting curves.
(C) DMS mapping data (left), enzymatic mapping
data (middle), and predicted hairpin structure of
r(GGGGCC)8 using mapping restraints (right). DMS
mapping lanes: 1, untreated RNA; 2, alkaline
hydrolysis; 3, T1 digestion under denaturing con-
ditions; 4, DMS modification in the presence of
185mM Li+; 5, DMSmodification in the presence of
185mMK+. Enzymatic mapping lanes: 1, untreated
RNA; 2, T1 digestion under denaturing conditions;
3, T1 digestion under native conditions; 4, V1
digestion in which base-paired nucleotides are
cleaved; 5, S1 digestion in which all single-
stranded nucleotides are cleaved.
(D) 1D 1H NMR spectra of r(GGGGCC)8 in the
presence of 100 mMK+ annealed at 37C, 60C, or
95C. Blue circles are imino proton resonances
from G residues present as base pairs and red
squares are imino proton resonances from non-
canonically paired G residues.
(E) Structures of lead compounds 1a, 2, and 3 that
bind to r(GGGGCC)8. See also Figure S1.
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Small-Molecule Modulators of (GGGGCC)exp RNAexpansion in human-induced pluripotent stem cell-derived
neurons (Donnelly et al., 2013; Sareen et al., 2013). In light
of pharmacological advantages, small molecules may offer
an attractive option for targeting r(GGGGCC)exp. Capitalizing on
our findings that r(GGGGCC)n adopts a hairpin structure
in addition to a G-quadruplex one, we designed small molecules
able to bind r(GGGGCC)exp and to significantly decrease
RAN translation and foci formation in cultured cells express-
ing r(GGGGCC)66, and induced neurons (iNeurons) directly con-
verted from fibroblasts of C9ORF72 repeat expansion carriers.
These findings indicate that designer small molecules targeting
r(GGGGCC)expmayprovepromisingasac9FTD/ALStherapeutic.
Furthermore, since we found that poly(GP) c9RAN proteins are
detected in c9ALS cerebrospinal fluid (CSF), poly(GP) proteins
may serve as a pharmacodynamic biomarker to assess efficacy
of potential therapies that target r(GGGGCC)exp.
RESULTS
r(GGGGCC)8 Preserves a Hairpin Structure with
Periodically Repeating 1 3 1 Nucleotide GG Internal
Loops in Equilibrium with a G-Quadruplex
With the goal of designing small-molecule modulators of
r(GGGGCC), we investigated its structure. Using evidence
from gel mobility shift assays and spectroscopic methods, pre-
vious reports suggest that r(GGGGCC) forms intra- and inter-
molecular G-quadruplex structures (Fratta et al., 2012; Reddy
et al., 2013), with another suggesting that r(GGGGCC) repeats1044 Neuron 83, 1043–1050, September 3, 2014 ª2014 Elsevier Inc.adopt both G-quadruplex and hairpin structures (Haeusler
et al., 2014). To further probe the structure of r(GGGGCC),
we completed spectroscopic (circular dichroism [CD] and
optical melting), chemical (modification with dimethyl sulfate
[DMS]), and enzymatic analyses (for a full description of our
biophysical studies see the Supplemental Information available
online). CD studies of r(GGGGCC)4, r(GGGGCC)6, and
r(GGGGCC)8 revealed that these RNAs probably fold into a
G-quadruplex structure in the presence of K+ but not Na+,
which promotes a hairpin structure (Figure 1A). We next studied
the structures of r(GGGGCC) by optical melting, as G-quadru-
plexes have signature melting curves (large hypochromic tran-
sition of UV absorbance at 295 nm) (Mergny et al., 1998). In
agreement with CD studies, optical melts completed in the
presence of Na+ indicated that r(GGGGCC)4, r(GGGGCC)6,
and r(GGGGCC)8 form intramolecular hairpins. In contrast,
optical melts completed in the presence of K+ indicate the
presence of both hairpin and G-quadruplex structures (Fig-
ure 1B and Table S1).
The folding of r(GGGGCC)8 was next examined using
enzymatic and chemical mapping in the presence of Li+ or
K+, the latter known to stabilize G-quadruplexes (Hardin
et al., 1992). Enzymatic mapping revealed an alternating
pattern of cleavage by enzymes that specifically cleave
paired or noncanonically paired nucleotides (Figure 1C), sug-
gesting that some populations form a hairpin structure. These
findings were confirmed using the chemical modification re-
agent DMS.
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Small-Molecule Modulators of (GGGGCC)exp RNAWe additionally explored the structure of r(GGGGCC)8 by
analyzing its 1D 1HNMRspectra. At low annealing temperatures,
the NMR spectra indicate that r(GGGGCC)8 folds into a hairpin
with noncanonically paired Gs in the stem (spectrum collected
at 37C; Figure 1D). As the annealing temperature increases,
however, NMR peaks become broad, indicating increased
population of a G-quadruplex. The existence of both confor-
mations is not surprising as other studies have suggested
RNAs that form quadruplexes can form alternative structures,
including hairpins (Bugaut et al., 2012).
Identification of Small Molecules that Bind
r(GGGGCC)exp
Exploiting the findings above, we sought to identify small mole-
cules that bind r(GGGGCC)exp and determine whether they
improve c9FTD/ALS-associated defects. It was reported that
TMPyP4, a known G-quadruplex binder, binds r(GGGGCC)8
in vitro (Zamiri et al., 2014). Although the bioactivity of TMPyP4
was not explored, these studies indicate that it is possible to
identify small molecules that bind r(GGGGCC) repeats. We
previously developed a strategy to design small molecules
that bind an RNA target using information about RNA-small
molecule interactions (Velagapudi et al., 2014). Small-molecule
leads can be further optimized by chemical similarity searching,
which identifies compounds that are chemically similar to the
leads. We reported that small molecule 1a binds 1 3 1 GG
internal loops present in r(CGG)exp and improves fragile X-asso-
ciated tremor/ataxia syndrome (FXTAS)-associated defects
(Disney et al., 2012). Given the structural similarity between
r(CGG)exp and r(GGGGCC)exp, we hypothesized that 1a and
compounds chemically similar to it might bind r(GGGGCC)exp.
We collected 132 such small molecules and screened them
for binding to r(GGGGCC)8. Three lead compounds (1a, 2,
and 3) were identified (Figures 1E and S1A; Table S2) and further
characterized. Kinetic binding studies showed that 1a, 2, and 3
bind to r(GGGGCC)8 with Kds of 9.7, 10, and 16 mM, respec-
tively, similar to those observed for r(CGG)12. In contrast, 1a,
2, and 3 bind more weakly to a hairpin with a fully paired
stem, suggesting that the compounds are at least modestly
selective (Figure S1B). We perturbed the equilibrium between
hairpin and G-quadruplex structures by folding r(GGGGCC)8 in
the presence of an additional 100 mM NaCl (favors hairpin) or
KCl (favors quadruplex). The observed Kds for 1a and 3 were
3- to 10-fold weaker in the presence of Na+ and K+, indicating
that ionic strength affects binding. Of interest, the affinity of 2
for r(GGGGCC)8 was not significantly affected by addition of
Na+, but became > 6-fold weaker in K+. These results indicate
that compound 2 recognizes the hairpin structure over the
G-quadruplex (Figure S1B).
Given that small-molecule binders of r(GGGGCC)exp may
influence the thermodynamic stability of the RNA, which could
in turn influence foci formation and RAN translation, optical
melting was used to study whether compounds increase
r(GGGGCC)8 stability. While compound 3 did not significantly
affect r(GGGGCC)8’s stability or melting temperature, 1a and 2
stabilized the RNA by 0.95 and 0.63 kcal/mol, respectively,
and increased the Tm by 3.1 and 1.9
C, respectively (Figure S1C
and Table S3).NeSmall-Molecule Binders of r(GGGGCC)exp Inhibit
RAN Translation and Foci Formation in
(GGGGCC)66-Expressing Cells
To determine whether compounds 1a, 2, and 3 bind
r(GGGGCC)exp in cells, we employed COS7 cells transfected
to express 66 GGGGCC repeats with no upstream ATG and
our previously reported strategy to identify small-molecule
cellular targets. In this strategy, small molecules are conjugated
to (1) a reactive module that forms a covalent cross-link with the
target (chlorambucil; CA); and (2) biotin for facile isolation of
small molecule-biomolecule adducts (Guan and Disney, 2013).
First, a biotin-chlorambucil conjugate of 1a was synthesized
(1a-CA-biotin; Figure 2A, Figures S2A and S2B), added to
(GGGGCC)66-expressing cells, and allowed to react with its
cellular targets. Biomolecule-small molecule adducts were
then isolated with streptavidin-functionalized resin. qRT-PCR
analysis of the isolated fractions showed an 80-fold enrichment
of r(GGGGCC)66 compared to 18S rRNA (normalized to un-
treated lysate; Figure 2B). To determine whether 1a, 2, and 3
bind r(GGGGCC)exp directly, we completed a competitive
profiling experiment by cotreating (GGGGCC)66-expressing cells
with 1a-CA-biotin and the compound of interest. That is, the
targets of 1a, 2, and 3 can be inferred by their depletion in pull-
down fractions. Indeed, the amount of r(GGGGCC)66 that forms
an adduct with 1a-CA-biotin was significantly depleted in the
presence of each compound (Figure 2B).
Having established that all three compounds bind r(GGG
GCC)66, we evaluated their effect on RAN translation. While
no evidence of RAN translation was seen in HEK293 cells ex-
pressing only 2 or 20 (GGGGCC) repeats, expression of
(GGGGCC)66 resulted in the synthesis of poly(GP) and poly(GA)
proteins (Figure 2C), but not poly(GR) proteins (not shown). Com-
pound 3 (100 mM, 24 hr) modestly inhibited synthesis of poly(GP)
proteins but did not influence poly(GA) protein production (Fig-
ure 2D). In contrast, compounds 1a and 2 significantly decreased
both poly(GP) and poly(GA) protein levels (Figure 2D). Given that
1a and 2 have similar effects on RAN translation and that 1a also
inhibits this event in iNeurons (shown below), we tested addi-
tional concentrations of 1a and found that it affords a dose-
dependent effect on RAN translation; statistically significant
decreases in poly(GP) of 10%, 18%, and 47% were detected
by immunoassay of lysates from (GGGGCC)66-expressing cells
treated with 25, 50, or 100 mM, respectively (Figure S2C).
In addition to the accumulation of c9RAN proteins, nuclear foci
are detected in (GGGGCC)66-expressing cells (Figure 2E).
Consistent with their effect on RAN translation, compounds
1a and 2, but not 3, significantly decreased the percentage of
foci-positive cells (Figure 2F). This was probably caused by
inhibition of foci formation, and not a result of impaired binding
of the probe to r(GGGGCC)66 in the presence of compound,
given that conducting RNA FISH on fixed, nontreated
(GGGGCC)66-expressing cells with a probe coincubated with
1a did not prevent detection of foci (Figure S2D).
Since the C9ORF72 repeat expansion is bidirectionally tran-
scribed in c9FTD/ALS, and since antisense transcripts contain-
ing (CCCCGG) repeats are also RAN translated and form foci
(Gendron et al., 2013; Mori et al., 2013a; Zu et al., 2013), we
evaluated the effect of 1a in r(CCCCGG)66-expressing cellsuron 83, 1043–1050, September 3, 2014 ª2014 Elsevier Inc. 1045
Figure 2. Small Molecules Targeting r(GGGGCC) Inhibit RAN Translation and Foci Formation in (GGGGCC)66-Expressing Cells
(A) Structure of 1a-CA-biotin; the chlorambucil moiety (CA) forms a covalent bond with the cellular target once the small molecule is bound. Biotin is used to
isolate biomolecule-small molecule adducts from cells.
(B) Normalized enrichment of r(GGGGCC)66 from biomolecules isolated with streptavidin beads as compared to 18S rRNA determined by qRT-PCR. Cells were
treated with 1a-CA-biotin alone or with 1a, 2, or 3 (competitive profiling). In competitive profiling experiments, the unreactive compound inhibits reaction of the
target with 1a-CA-biotin and thus the target is depleted in pull-down fractions. Data presented as mean ± SD (n = 2).
(legend continued on next page)
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Small-Molecule Modulators of (GGGGCC)exp RNApreviously shown to express poly(PR) and poly(GP) proteins
(Gendron et al., 2013). Whereas 1a (100 mM, 24 hr) significantly
decreased poly(GP) proteins RAN translated from sense tran-
scripts (Figure 2G), it had no effect on poly(GP) or poly(PR)
proteins RAN translated from antisense r(CCCCGG)66, as
assessed by immunoassay (Figure 2H; see Figures S2E and
S4A for assay validation). Likewise, no change in the percentage
of cells bearing r(CCCCGG) foci was detected following 1a
treatment (Figure 2I). In contrast, we reported that 1a does
reduce foci in r(CGG)60-expressing cells (Disney et al., 2012),
and we show here that 1a also inhibits RAN translation in cells
expressing (CGG)88 placed in the 5
0-UTR of GFP, but does not
affect downstream canonical translation (Figure 2J). These
results confirm the structural similarity between r(CGG)exp and
r(GGGGCC)exp in cells and the selectivity of 1a toward this
structure.
Small-Molecule Binders of r(GGGGCC) Inhibit
RAN Translation and Foci Formation in
(GGGGCC)exp-Expressing iNeurons
To establish a more physiological disease cell model, fibroblasts
with or without the C9ORF72 repeat expansion were directly
converted to a neuronal lineage by repressing polypyrimidine-
tract-binding protein (PTB1), as recently described (Xue et al.,
2013). PTB1 depletion caused fibroblasts to adopt a neuronal
morphology with reduced soma size and neurite formation (Fig-
ures 3A, 3B, and S3A). These iNeurons expressed neuronal and
synaptic markers, including MAP2, TUJ1, PSD95, Synapsin I,
and Drebrin (Figures 3A and S3B). Nuclear foci, degraded by
RNase A but resistant to DNase I (Figure S3C), were present in
both C9ORF72+ fibroblasts (Figure S3D) and iNeurons (Fig-
ure 3C). Cytoplasmic poly(GP) inclusions, as well as poly(PR)
inclusions, were also present in C9ORF72+ iNeurons (Figure 3C)
but were not found in parental fibroblasts (Figure S3E). No foci
or poly(GP) inclusions were detected in iNeurons lacking
the expanded repeat (Figure 3C). Of importance, in three
C9ORF72+ iNeuron lines, compound 1a significantly decreased
the percentage of cells with RNA foci (Figure 3D) and poly(GP)
inclusions (Figures 3E and 3F), while having no effect on
C9ORF72 mRNA levels (Figure S3F). Consistent with findings
in (GGGGCC)66-expressing cells, a dose-dependent decrease
in RAN translation of poly(GP) was observed in 1a-treated
C9ORF72+ iNeurons, but no change in poly(PR) expression,
which is synthesized from the antisense transcript, was detected
(Figure S3G). Due to toxicity associated with compound 2(C) Cells overexpressing 66 (GGGGCC) repeats (C9-66R), but not 2 (C9-2R)
nonspecific bands.
(D) Western blot and densitometry of poly(GP) and poly(GA) proteins in (GGGGC
24 hr). Data represent mean + SEM (n = 3).
(E) RNA foci (red) are detected in the nucleus (Hoechst; blue) of C9-66R cells.
(F) Evaluation of the percentage of foci-positive cells by RNA FISH posttreatmen
(G and H) Compound 1a decreases RAN translation of poly(GP) proteins from se
poly(GP) or poly(PR) proteins RAN translated from antisense (CCCCGG)66 repe
represent mean + SEM (n = 3 or 4).
(I) The percentage of r(CCCCGG)-containing foci in C9-AS-66R cells is not affec
(J) 1a decreases RAN translation of poly(G) in cells expressing (CGG)88 upstream
*p < 0.05, **p < 0.01, ***p < 0.001, as assessed by one-way ANOVA followed by D
Figure S2.
Nein iNeurons, it was not tested in this model. Taken together,
our data indicate that our strategy to design small-molecule
modulators of r(GGGGCC) led to the successful identification
of a compound that mitigates abnormal events initiated by
r(GGGGCC)exp.
Poly(GP) Proteins Are Detected in c9ALS CSF
Our findings above indicate that r(GGGGCC)exp-targeting
small molecules can inhibit foci formation and RAN translation.
Consequently, if c9RAN proteins are detected in CSF, they
have the potential to serve as a measurable indicator of thera-
peutic efficacy. To test this notion, we developed a poly(GP) pro-
tein immunoassay (Figure S4A) and validated it as a sensitive
means to measure endogenous poly(GP) using soluble fractions
of frontal cortex tissues. As expected, poly(GP) was specifically
detected in c9FTD/ALS samples (Figure S4B).
To test poly(GP) proteins as clinically relevant biomarkers,
we evaluated whether they are detectable in CSF. We analyzed
CSF from 14 c9ALS patients in comparison to CSF from 25 ALS
patients without the C9ORF72 mutation and 5 healthy subjects
(see Table S4 for patient details). As shown in Figure 4A, poly(GP)
proteins were detected only in c9ALSCSF. Using a (GP)8 peptide
standard curve, we estimate the median concentration of
poly(GP) in c9ALS CSF to be 0.67 ng/ml (Figure S4C, Table S4).
These exciting findings provide an important first step in identi-
fying pharmacodynamic biomarkers for c9FTD/ALS (Figure 4B).
DISCUSSION
In the present study, we provide evidence that (1) r(GGGGCC)exp
adopts both hairpin and G-quadruplex structures—information
important for the design of r(GGGGCC)-binding small molecules;
(2) human fibroblasts can be directly converted to neurons that
recapitulate salient features of disease; (3) small molecules
that bind r(GGGGCC)exp inhibit RAN translation and foci forma-
tion; and (4) c9RAN proteins are detectable in c9ALS CSF.
Recent studies show that r(GGGGCC) repeats forms G-quad-
ruplexes (Fratta et al., 2012; Reddy et al., 2013), with another
reporting they adopt both G-quadruplex and hairpin structures
(Haeusler et al., 2014). In agreement with the latter, our chemical
and enzymatic probing studies reveal that r(GGGGCC)8 do form
a hairpin structure. NMR studies suggest that the hairpin
structure predominates at low refolding temperatures while the
quadruplex predominates at higher ones. To understand the
finer details of this equilibrium in cells, chemical mapping couldor 20 (C9-20R), express poly(GP) and poly(GA) proteins. Asterisks demark
C)66-expressing cells treated with DMSO or compounds 1a, 2, or 3 (100 mM,
t. Data represent mean + SEM in ten fields.
nse (GGGGCC)66 repeats in C9-66R cells (G) but does not influence levels of
ats in C9-AS-66R cells (H), as assessed by GP and PR immunoassays. Data
ted by 1a.
of GFP. Data presented as mean + SEM (n = 3).
unnett’s Multiple Comparison Test. ##p < 0.01, as assessed by t test. See also
uron 83, 1043–1050, September 3, 2014 ª2014 Elsevier Inc. 1047
Figure 3. Small Molecules Targeting
r(GGGGCC) Inhibit RAN Translation and
Foci Formation in iNeurons with the
C9ORF72 Expansion
(A) Immunofluorescence staining of fibroblasts
transduced with nonsilencing shRNA or shPTB1
for PTB1 and the neuronal marker, MAP2. Scale
bar, 20 mm.
(B) PTB1 western blot analysis of fibroblasts
transduced or not with shPTB1.
(C) RNA foci accumulate in iNeurons with the
C9ORF72 repeat expansion (C9ORF72+) but not in
iNeurons lacking the expansion (C9ORF72-), as
assessed by RNA FISH. Immunofluorescence
staining with anti-GP or anti-PR illustrates the
accumulation of c9RAN proteins specifically in
C9ORF72+ iNeurons. Scale bars, 5 mm.
(D) Treatment of C9ORF72+ iNeurons with com-
pound 1a (2 mM, 4 d) significantly decreased
the percentage of cells with foci. For each iNeuron
line, data reflects the average percentage of
foci-positive cells + SEM in three separate fields.
(E and F) Compound 1a significantly decreased
the percentage of cells with anti-GP, but not anti-
PR, immunoreactive inclusions (magnification:
203). For each line, data represent the average
percentage of inclusion-positive cells + SEM
counted in nine wells of a 96-well plate. #p < 0.05,
##p < 0.01, as assessed by t test. See also Fig-
ure S3.
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Small-Molecule Modulators of (GGGGCC)exp RNAbe completed as described in yeast (Wells et al., 2000), although
readout using reverse transcriptase could be challenging. Alter-
natively, antibodies that recognize RNA quadruplexes could be
employed (Lam et al., 2013).
We identified three compounds that bind r(GGGGCC) (1a, 2,
and 3), two of which significantly inhibited RAN translation and
foci formation in a novel r(GGGGCC)66 cell model developed
for the rapid screening of drugs. In addition, we found that 1a
inhibits RAN translation and foci formation in C9ORF72+
iNeurons. This report shows that adult human fibroblasts can
be directly converted to neurons that mirror disease-specific
defects and that these defects can be blocked by pharmacolog-
ical manipulation. Of interest, RNA foci were observed in both
C9ORF72+ fibroblasts and iNeurons, while poly(GP) and
poly(PR) inclusions were observed in iNeurons but not fibro-
blasts. These findings are consistent with our observation that
poly(GP) inclusions are restricted to neurons in c9FTD/ALS
(Ash et al., 2013).
There are at least two mechanisms by which our small
molecules may affect RAN translation. In the first model, their1048 Neuron 83, 1043–1050, September 3, 2014 ª2014 Elsevier Inc.binding to r(GGGGCC)exp increases the
thermodynamic stability of the RNA and
is thus an impediment for ribosomal
read-through of the transcript. Indeed,
1a and 2 stabilize r(GGGGCC)8 in vitro.
In a second model, the binding of small
molecules to the repeats impedes initia-
tion of translation at these sites. In a
similar fashion, the decrease in fociobserved upon treatment could result from the inability of 1a-
or 2-bound r(GGGGCC)exp to bind RBPs that promote foci
formation.
As a pathological hallmark of c9FTD/ALS, and one that is influ-
enced by r(GGGGCC)exp-targeting small molecules, c9RAN pro-
teins have potential to serve as clinically relevant biomarkers.
Our discovery that poly(GP) is detectable specifically in c9ALS
CSF could facilitate identification of C9ORF72 repeat expansion
carriers in the course of diagnostic work-ups and pave the way in
determining whether changes in c9RAN protein levels in CSF
correlate with disease severity or progression. Of importance,
CSF c9RAN proteins could serve as an enrollment stratification
tool in clinical trials and a pharmacodynamic biomarker to
assess efficacy of therapies that target r(GGGGCC)exp (Fig-
ure 4B). While these critical questions are investigated, it
should be kept in mind that the C9ORF72 expansion is bidirec-
tionally transcribed (Gendron et al., 2013; Mori et al., 2013a;
Zu et al., 2013); as such, therapeutics may have to target both
r(GGGGCC)exp and r(CCCCGG)exp. Because poly(GP) proteins
are produced by RAN translation of sense and antisense
Figure 4. Poly(GP) Proteins Are Detected in c9ALS Cerebrospinal
Fluid
(A) Poly(GP) expression in CSF from five healthy individuals, 25 ALS patients
negative for the C9ORF72 repeat expansion, and 14 c9ALS patients were
Neuron
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Netranscripts, poly(GP) immunoassays, such as the one described
herein, could be of great use in testing therapeutics toward both
r(GGGGCC)exp and r(CCCCGG)exp.
EXPERIMENTAL PROCEDURES
For 1H NMR spectroscopy, r(GGGGCC)8 (600 mM) was prepared in 10 mM
Tris HCl, pH 7.,4 and 100mMKCl and annealed at the appropriate temperature
for 5 min and allowed to cool to room temperature. After equilibration for 2 hr,
NMR spectra were recorded at 10C.
To identify RNA targets of 1a, 2, and 3, COS7 cells expressing r(GGGGCC)66
were treated with 1a-CA-Biotin and compound of interest. Total RNA was
extracted 24 hr later and incubated with streptavidin beads. cDNA was gene-
rated from bound RNA-1a-CA-Biotin adducts released from beads for quan-
titation of r(GGGGCC)66 by qPCR. To detect products of RAN translation,
lysates were prepared from (GGGGCC)n-expressing HEK293 cells treated or
not with compound for western blotting using anti-GP, anti-GA, or anti-GR
antibodies. The effect of 1a was also tested in cells expressing r(CGG)88
embedded in the 50-UTR of an open reading frame encoding GFP to allow
detection of RAN-translated products by western blot using anti-GFP.
Poly(GP) or poly(PR) expression in (GGGGCC)n-expressing cells, human
brain lysates, and CSF were evaluated by sandwich immunoassays. Foci in
(GGGGCC)n-expressing cells were visualized by RNA FISH using a Cy3-
(GGCCCC)4 probe.
Fibroblasts derived from patient skin samples were converted to iNeurons
by transduction with pLKO.1 coding for shPTB1 (Xue et al., 2013). Poly(GP)
and poly(PR) expression in iNeurons treated or not with 1a were evaluated
by immunofluorescence staining and foci were visualized by FISH using a
locked nucleic acid probe (50-TYE563-CCCCGGCCCCGGCCCC-30). RNA
extracted from iNeurons was utilized for qRT-PCR analysis of C9ORF72
mRNA expression.
Data are presented as the mean ± SEM from a minimum of three ex-
periments unless otherwise indicated. Statistical comparisons were made by
Student’s t test or ANOVA. Statistical significance was inferred at p < 0.05.
For more details on all methods, please see Supplemental Information.
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